Johnson & Johnson (JNJ) Stock Price, Quote & News

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 732 524 0400

Website: www.jnj.com

Address:

One Johnson & Johnson Plaza, New Brunswick, United States

dewmoore Jul. 12 at 2:15 PM

$SLS 🚨 BREAKING MATH: If the REGAL trial unblinds at 80 events and the control group accounts for all 63, the GPS arm is left with just 17 events. To hit its own (MOS), the GPS group needs *32 events* BUT if only 17 died, the GPS arm literally CANNOT reach its MOS at the final readout. The CEO continues to say he expects GPS to match or exceed the Phase 2 trial results (3 times longer) than the current standard of care (21.0 months vs. 5.4 months). If the GPS group sits at only 17 events at the 80th death, it would require an additional **15 events** just to touch its MOS. At the current slow rate ,they wouldn't hit a GPS MOS until NEXT YEAR **6 years** since the trial started + nearly 3 YEARS since the very last patient was dosed. A trial running this long with a "GPS MOS NOT Reached" = sMIRACLE! Wall Street is completely blind to a potential **$50+ explosion** if these dynamics lock in. The shorts are trapped and the buyout battle between these 4 $LLY $PFE $MRK $JNJ goes CRAZY!!

3 · Reply

ElliottwaveForecast Jul. 12 at 11:05 AM

📢 $JNJ Bullish Rally Targets $271.37+ 💊 Johnson & Johnson is unfolding a bullish Elliott Wave sequence. The current structure favors continued upside, with projections pointing toward $271.37 and potentially beyond. Read the Full analysis 👉 https://elliottwave-forecast.com/stock-market/jnj-elliott-wave-bullish-rally-targets-271-37-beyond/ #ElliottWave #Trading #Stocks

0 · Reply

FantasyFin Jul. 12 at 9:32 AM

$JNJ The healthcare giant is a defensive anchor. Strong pharma pipeline and consumer health spin-off unlocked value for shareholders.

0 · Reply

DonVigo Jul. 12 at 7:21 AM

$ABBV $MRK $PFE $JNJ

0 · Reply

Suite510 Jul. 11 at 10:05 PM

$JNJ $KVUE oh look another 22M verdict plus the 45M verdict that’s 67M in only 2 days pay up lol 😂 Superior Court Nixes Bid For New Talc Trial Arising From $22M Verdict' On appeal, the plaintiffs argued that simply molding the verdict to reflect the jury's decision on causation wasn't enough to cure the inconsistency.

0 · Reply

Suite510 Jul. 11 at 9:27 PM

$JNJ $KVUE And the hits just keep on coming 😂 Ill. Appeals Court Upholds $45M Talc Verdict Against J&J A split Illinois state appeals court on Friday refused to disturb a jury's verdict awarding $45 million to the family of a woman who developed mesothelioma and died after using Johnson & Johnson's talc baby powder for decades.

0 · Reply

MRTunity Jul. 11 at 2:30 PM

$SLS someone if not $JNJ it will be one of $PFE , $MRK or $BMY who scoops us up very very soon! Regal topline and FA will finally shut the naysayers and trolls up OMCE AND FOR ALL 🚀 🌙

0 · Reply

clan Jul. 10 at 11:06 PM

$MNKD In < 4 wks, might we get an update on pre-clinical MNKD-102's resurrection? 🤔 Just say, No to leporacy and red skin. #isperse #hasbeenprogressing $JNJ $MRK

0 · Reply

Ron_Burn Jul. 10 at 10:15 PM

$JNJ thin momentum at the top, need more data, so check back in a week or two

0 · Reply

Lord_Burglekutt Jul. 10 at 5:42 PM

$SRXH Company is buying back half of the float. It was already a low float. Guess what happens then? We fly so high. 🤑 $GOOGL $AVGO $PFE $JNJ We all are going to get rich off this. Went from .96 to 3.20 in 24 hours. Need a cool down and reload. LFG 🔥

0 · Reply

Johnson & Johnson price target raised to $263 from $254 at BofA

2026-07-09T19:09:11.000Z - 2 days ago

3 ‘Strong Buy’ Dividend Aristocrat Stocks, According to Top Analysts — July 9, 2026

CTAS CVX

Jul 9, 2026, 1:00 PM EDT - 2 days ago

The Big 3: UNH, KO, JNJ

KO UNH

2026-07-08T11:50:22.000Z - 4 days ago

Johnson & Johnson announces FDA approval for THERMOCOOL SMARTTOUCH SF

Jul 8, 2026, 7:45 AM EDT - 4 days ago

Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform

2026-07-08T11:40:29.000Z - 4 days ago

Johnson & Johnson price target raised to $284 from $283 at Morgan Stanley

2026-07-08T10:40:49.000Z - 4 days ago

Johnson & Johnson price target raised to $298 from $285 at Citi

Jul 6, 2026, 6:29 PM EDT - 5 days ago

Jim Cramer says these are the 5 stocks to buy during this market rotation

PEP SBUX STZ TJX

2026-07-06T14:25:32.000Z - 6 days ago

Johnson & Johnson price target raised to $290 from $280 at HSBC

Jun 26, 2026, 2:39 PM EDT - 15 days ago

Healthcare stocks have become a haven for investors ditching tech

ABBV ABSI APGE LLY MRNA SNY XBI

2026-06-26T16:40:11.000Z - 15 days ago

Johnson & Johnson presents new Imaavy data at EAN 2026 Congress

Jun 26, 2026, 12:35 PM EDT - 15 days ago

Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

2026-06-26T12:36:03.000Z - 16 days ago

Johnson & Johnson price target raised to $270 from $266 at Guggenheim

2026-06-25T09:10:22.000Z - 17 days ago

Johnson & Johnson launches Dual Energy Thermocool Smarttouch in Europe

Jun 25, 2026, 5:00 AM EDT - 17 days ago

Johnson & Johnson Advances Cardiac Ablation Technology in Europe with Availability of Dual Energy THERMOCOOL SMARTTOUCH SF Platform

Jun 15, 2026, 6:00 AM EDT - 27 days ago

Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida

$New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma$

Jun 13, 2026, 6:41 AM EDT - 4 weeks ago

New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma

$New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma$

Jun 13, 2026, 6:33 AM EDT - 4 weeks ago

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

Jun 11, 2026, 7:45 AM EDT - 4 weeks ago

Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients

Jun 11, 2026, 7:14 AM EDT - 4 weeks ago

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

ABBV ALKS AMGN GILD IBB IHE KYMR

Jun 11, 2026, 2:03 AM EDT - 4 weeks ago

IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies

Jun 10, 2026, 11:22 AM EDT - 4 weeks ago

Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos Trial

Jun 10, 2026, 6:20 AM EDT - 4 weeks ago

Johnson & Johnson CEO Says Cure for Certain Cancers Is Realistic Goal

Jun 9, 2026, 10:00 AM EDT - 4 weeks ago

Johnson & Johnson Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 9:20 AM EDT - 4 weeks ago

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

AMGN LLY MRK NVO PFE

Jun 8, 2026, 9:01 AM EDT - 4 weeks ago

Johnson & Johnson to Buy Firefly Bio for $1 Billion

Jun 8, 2026, 8:08 AM EDT - 4 weeks ago

Johnson & Johnson to buy Firefly Bio for $1 billion

Jun 8, 2026, 8:00 AM EDT - 4 weeks ago

Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform

Jun 5, 2026, 6:24 PM EDT - 5 weeks ago

J&J beats lawsuit alleging that talc caused three women's cancer

Jun 3, 2026, 12:04 AM EDT - 5 weeks ago

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

SLE

Jun 3, 2026, 12:03 AM EDT - 5 weeks ago

Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease

Jun 2, 2026, 6:24 PM EDT - 5 weeks ago

Jim Cramer says look to buy these 5 stocks outside the AI trade for diversification

JPM KMB MCD YUM

May 31, 2026, 8:39 AM EDT - 6 weeks ago

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, versus hormone therapy alone, potentially shifting a decades-long treatment paradigm

May 31, 2026, 8:29 AM EDT - 6 weeks ago

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited

May 31, 2026, 8:27 AM EDT - 6 weeks ago

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm

May 31, 2026, 8:01 AM EDT - 6 weeks ago

J&J prostate cancer drug reduces risk of cancer spread and death in late-stage study

May 29, 2026, 2:00 PM EDT - 6 weeks ago

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer

May 29, 2026, 8:18 AM EDT - 6 weeks ago

New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma

May 28, 2026, 7:10 PM EDT - 6 weeks ago

FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage

May 28, 2026, 5:30 AM EDT - 6 weeks ago

J&J Mastered Cancer Biotech Deals on the Cheap. Can It Stay on the Cutting Edge?

May 27, 2026, 4:22 PM EDT - 6 weeks ago

Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

May 27, 2026, 11:00 AM EDT - 6 weeks ago

Johnson & Johnson Transcript: Bernstein 42nd Annual Strategic Decisions Conference

May 21, 2026, 7:00 AM EDT - 7 weeks ago

Johnson & Johnson Advances Creation of Global Intelligent OR Network in collaboration with Department of Health - Abu Dhabi

May 21, 2026, 4:31 AM EDT - 7 weeks ago

Johnson & Johnson says nipocalimab approved in China

May 19, 2026, 11:30 AM EDT - 7 weeks ago

Johnson & Johnson Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 19, 2026, 9:00 AM EDT - 7 weeks ago

Portal Innovations and New Brunswick Development Corporation Collaborate with Johnson & Johnson to Name the Johnson & Johnson Exchange at the New Jersey Innovation Hub in HELIX, Advancing the State's Life Sciences Leadership

May 14, 2026, 4:01 PM EDT - 2 months ago

Groundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovation

STGW

May 12, 2026, 2:20 PM EDT - 2 months ago

Johnson & Johnson Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 7:45 AM EDT - 2 months ago

Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter

May 11, 2026, 4:34 PM EDT - 2 months ago

Johnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

May 11, 2026, 8:00 AM EDT - 2 months ago

Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP

May 7, 2026, 11:34 AM EDT - 2 months ago

This Dividend Pro Likes Banks, Semi-Equipment Stocks, Altria, and J&J

May 7, 2026, 8:00 AM EDT - 2 months ago

Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission

May 5, 2026, 9:15 AM EDT - 2 months ago

CVS to drop J&J's Stelara from its main formularies

CVS

May 5, 2026, 8:05 AM EDT - 2 months ago

Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease

$Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease$

May 5, 2026, 8:05 AM EDT - 2 months ago

Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease

May 5, 2026, 7:00 AM EDT - 2 months ago

Johnson & Johnson Announces Pivotal Clinical Study Results for a New Soft-Tissue Surgical Robotic System

May 4, 2026, 8:00 AM EDT - 2 months ago

CAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis

May 2, 2026, 4:00 AM EDT - 2 months ago

J&J's $1.7 Billion Drug Ushers in Age of Psychedelic Medicine

Apr 30, 2026, 8:02 AM EDT - 2 months ago

Johnson & Johnson Appoints Ryan Koors as Vice President, Investor Relations

Apr 28, 2026, 11:10 AM EDT - 2 months ago

Why These 3 Forever Stocks Belong on Your Watchlist

WMT XOM

Apr 27, 2026, 4:33 PM EDT - 2 months ago

Johnson & Johnson to Participate in the Bernstein's 42nd Annual Strategic Decisions Conference

Apr 27, 2026, 11:03 AM EDT - 2 months ago

J&J sees AI halving the time to generate drug development leads

dewmoore Jul. 12 at 2:15 PM

3 · Reply

ElliottwaveForecast Jul. 12 at 11:05 AM

0 · Reply

FantasyFin Jul. 12 at 9:32 AM

$JNJ The healthcare giant is a defensive anchor. Strong pharma pipeline and consumer health spin-off unlocked value for shareholders.

0 · Reply

DonVigo Jul. 12 at 7:21 AM

$ABBV $MRK $PFE $JNJ

0 · Reply

Suite510 Jul. 11 at 10:05 PM

0 · Reply

Suite510 Jul. 11 at 9:27 PM

0 · Reply

MRTunity Jul. 11 at 2:30 PM

$SLS someone if not $JNJ it will be one of $PFE , $MRK or $BMY who scoops us up very very soon! Regal topline and FA will finally shut the naysayers and trolls up OMCE AND FOR ALL 🚀 🌙

0 · Reply

clan Jul. 10 at 11:06 PM

$MNKD In < 4 wks, might we get an update on pre-clinical MNKD-102's resurrection? 🤔 Just say, No to leporacy and red skin. #isperse #hasbeenprogressing $JNJ $MRK

0 · Reply

Ron_Burn Jul. 10 at 10:15 PM

$JNJ thin momentum at the top, need more data, so check back in a week or two

0 · Reply

Lord_Burglekutt Jul. 10 at 5:42 PM

0 · Reply

BarkingPuppy Jul. 10 at 4:17 PM

$ELTP $PFE $JNJ $MRNA $GME This is why ELTP is going to be the biggest stock of 2027. Its all about SequestOx... Here is the info. Look it up. Why SequestOx is Great Addresses the Opioid Crisis: With opioid addiction being a major public health issue, SequestOx offers a safer alternative for patients who need strong pain relief but are at risk of misuse or abuse. Effective Pain Relief: The oxycodone component ensures that patients receive immediate and effective relief from moderate to severe pain, improving quality of life. Innovative Abuse-Deterrent Design: The sequestered naltrexone technology is a significant advancement in pharmaceutical formulations, combining efficacy with safety. Regulatory Progress: SequestOx has been under development with regulatory filings and pivotal bioequivalence studies underway, highlighting ELTP’s commitment to bringing this important medication to market.

1 · Reply

IN0V8 Jul. 10 at 2:56 PM

$JNJ BofA Global Research raises price objective to $263 from $254

0 · Reply

HydrogenH2 Jul. 10 at 2:44 PM

$JNJ Cramer "pimping" JNJ again at this level ??

0 · Reply

BarkingPuppy Jul. 10 at 1:15 PM

$ELTP $PFE $MRNA $JNJ

0 · Reply

ElliottwaveForecast Jul. 10 at 11:16 AM

$JNJ the current pullback should remain supported in 3, 7 or 11 swings against June-2026 low to continue rally It expect at least one or few more highs to extend May-2026 sequence above 271.37 or higher to extend January-2025 bull run in impulse. https://elliottwave-forecast.com/stock-market/jnj-elliott-wave-bullish-rally-targets-271-37-beyond/ #Elliottwave #JNJ

0 · Reply

ElliottwaveForecast Jul. 10 at 12:54 AM

$JNJ should continue rally targeting 271.37 or higher within daily bull run against May-2026 low. Short term pullback against 6.22.2026 low should remain supported to continue rally to extend ((5)). Check out the details at https://elliottwave-forecast.com/stock-market/jnj-elliott-wave-bullish-rally-targets-271-37-beyond/ #Elliottwave #Trading

0 · Reply

JAGTTMAL Jul. 10 at 12:23 AM

$ISRG $JNJ is going to destroy these idiots, JNJ will throw weight around with the FDA, bet they launch with a stapler on OTTAVA

1 · Reply

ElliottwaveForecast Jul. 9 at 11:09 PM

$JNJ Bullish Rally Update JNJ continues to favor upside in wave ((5)), with the next key target at $271.37 . Structure shows strength from the BlueBox area and supports continuation higher while the pivot holds . A break above $271.37 opens the door toward $305.3 in the daily view . Full analysis: 👉 https://elliottwave-forecast.com/stock-market/jnj-elliott-wave-bullish-rally-targets-271-37-beyond/ #JNJ #ElliottWave #Stocks #Trading

0 · Reply

Mountainmannn Jul. 9 at 9:23 PM

$ABUS $MRNA has to protect their Cancer delivery LPN line promised in negotiations during settlement for release on virus vaccines.. $PFE fighting to protect their ass and gain access to a new drug line. $JNJ just there messing with everyone's wallets because they can.. hahaha tables served let's eat!!

1 · Reply

parcha Jul. 9 at 8:57 PM

https://youtube.com/watch?v=3ua9yss0CA0&is=Sd_X_Kjy0CuJtJNW $JNJ

0 · Reply

MorganHoratio Jul. 9 at 7:23 PM

Best Robot Stocks 6. Medical and Surgical Robots $JNJ $SYK $SNN $ZBH $GMED While cloud-AI narratives swing, medical robotics stands out for defensive growth and tangible monetization. These tickers represent the infrastructure bedrock of automated healthcare. JNJ expands its MedTech moat as its soft-tissue robotic platform, OTTAVA, officially enters FDA review with stellar clinical data. SYK, the undisputed orthopedic titan, drives massive Mako expansions into shoulder procedures alongside its Mako RPS handheld system targeting surgery centers. Meanwhile, ZBH, SNN, and GMED secure high-margin clinical moats through ROSA, CORI, and ExcelsiusGPS platforms. Aging demographics deliver a structural mandate for hospital efficiency. Is surgical robotics the ultimate compounding play? Which asset holds the deepest moat: JNJ or SYK? Drop your positions below!

0 · Reply

SwingTradeMaestro Jul. 9 at 5:36 PM

$JNJ $ABBV on sale for no reason. Yes please

0 · Reply

Market Cap	618.61B
Revenue (ttm)	94.19B
Net Income (ttm)	26.80B
EPS (ttm)	N/A
PE Ratio	24.15
Forward PE	22.37
Profit Margin	28.46%
Debt to Equity Ratio	0.46

Volume	6,534,700
Avg Vol	8,166,536
Day's Range	N/A - N/A
Shares Out	2.41B
Stochastic %K	32%
Beta	0.24
Analysts	Strong Sell
Price Target	$262.20